We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.925 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/3/2017 11:58 | people are buying these still ?!! | luminoso | |
07/3/2017 11:58 | What a car crash. The problem for cancer patients is that it will now probably take time to prise this potentially great technology out of the BOD's grubby hands via a fire sale further down the road. | luminoso | |
07/3/2017 11:03 | Blueball - there are real issues if this goes below 25p. Have a read of what TW says here: hxxp://www.shareprop | jestercat2 | |
07/3/2017 10:44 | That really brings it home, 15p was about what they were worth in apr 15, except of course that was in "old money" | cosmicboy | |
07/3/2017 10:11 | My guess is they are worth 15p. | blueball | |
07/3/2017 10:05 | From Shareprophets this morning: "Last night the company had a presentation in London. It has another in Zurich this morning. Warning Swiss folk and tax dodgers quotes about the London chingwag include "everyone left unhappy" and from a long term bull "I am just throwing in the towel." FFS | jestercat2 | |
07/3/2017 10:03 | Cheers guys. Just an idle thought. Thing is as a shareholder, when you sue the Co, you are actually suing yourself in a sense. If you win, it's like a special Divi, but still more net value out of the company....and only after Co burns cash "defending itself". It's individual directors who should get it in the neck. You have to believe, that as most are senior clinicians with hard won reputations to lose, that they are just extremely naive and not knowingly dishonest. As I’m sure others would agree, what we need now is a few less clinicians on big salaries and a few more hard-headed honest and savvy business peeps. | gerhart | |
07/3/2017 10:00 | Well I am game for a go at them in the courts. Lying to obtain pecuniary advantage has always been a crime. | euroto | |
07/3/2017 09:53 | Gerhart - see the Elektron Technology PLC (LSE:EKT) board Where the poster Simon Templar QC has been / is taking legal action against certain members of the board for destroying company value. | someuwin | |
07/3/2017 09:51 | yes never mind - one moves on | twirl | |
07/3/2017 09:43 | Are there any examples of shareholders sucessfully suing their own BOD, as a company or individual directors, for misleading information. | gerhart | |
07/3/2017 09:07 | I may be at the bottom of the class, but you should all still have listened to me! Too many investors here fell in love with the cancer curing aspects of the company, and neglected to believe what was actually going on. | igbertsponk | |
07/3/2017 08:54 | twirl, not altruistic and never short and only briefly invested but kept an interest because the tech does/did have promise but like many investors in AIM, sick of being lied to. twirl - 19 Aug 2016 - 09:29:21 - 2198 of 3004 Advanced Oncotherapy (AVO) - formerly CareCapital - AVO Unfortunately the Harley St project provides a welcome opportunity for the de rampers such as waterloo001, Igbert and possibly atom to cast doubt and fear amongst those holders who have short time horizons or are ignorant about AVO. Such derampers do this in the hope that those investors will sell allowing others to buy in at a lower level. The main purpose of AVO is to develop, manufacture,sell and maintain LIGHT machines. The main business is not to manage care provision such as Harley St or Pebble Mill. That is what Michael Sinclair said at the AGM. The outcome of the testing is therefore of paramount importance and the planning application is not. However an unsuccessful planning outcome would be taken as an opportunity to depress the share price by the market and will provide a buying opportunity. I do not expect an unsuccessful outcome as AVO have never failed to deliver. Derampers typically do not own shares in the company and post out of apparantly altruistic motives to warn holders of the dangers of holding the stock. The response of Igbert to my Q re the most substantive issue for AVO demonstrated his/her ignorance of AVO. Igbert failed to say successful testing of LIGHT - go to the bottom of the class Igbert. The failure by atom to substantiate his/her rumour re planning again undermines integrity. Waterloo001 either has sold up or has never held and is looking to buy in at a lower price - otherwise I salute you waterloo001 for you altruistic concerns for the welfare of AVO shareholders. | waterloo01 | |
07/3/2017 08:44 | Death spiral speeds up. Sad, but inevitable. | igbertsponk | |
07/3/2017 08:40 | Gutted I missed this as a short. It was nailed on. | loglorry1 | |
07/3/2017 08:36 | This was all discussed and out in the open in June, just not disclosed by the lying toe rags at the company You've had 9 months to get out, you don't often get that much warning. It's one of the issues with Cern. Very good at spending huge amounts of public money ($13,2bn) with minimal results. I think the BOD still think they are playing with public money. | waterloo01 | |
07/3/2017 08:30 | They are not close to producing a working prototype, they are still module testing and have not begun integrating the system yet. No wonder the Chinese hospitals walked. No other customer could expect delivery until 2021 or maybe 2022. There will be no sales to replace the lost ones, no wonder Sinophi also walked. In the meantime the death spiral will destroy the share price. Maybe look to buy in 2020 if they are still going. | sweet karolina | |
07/3/2017 08:22 | I think what the latest info and the presentations do is set the clock to zero/clean slate. Start again, in terms of enticing new investors, with a clearer shorter time frame, but still the risks. But also now with the Bracknor shadow hanging over the share price. Hopefully the effect of the former will be much stronger than the latter. But whatever, the BOD, despite all their great credentials, were either very naive, or very dishonest, when they previously said next funding would not be dilutive. All is not lost by a long way, and I still think TW is too negative, perhaps in a sense engaging in a self-fulfilling prophecy. But if we could afford to lose some of the BOD without affecting prospects, then I certainly think one or two should be out. But I would rather swallow hard now if that makes future prospects more secure. | gerhart | |
06/3/2017 18:55 | If the management have confidence in their product, which I am sure they do have, and if they are close to producing a working prototype, which it would seem from todays reports that they are, then I don't understand why they were unable to go to a reputable financial institution or bank with a positive compelling story and secure proper debt finance with decent terms and conditions. Instead they go to the equivalent of a pay-day loans shark. Very sad. And they must have been very naive if they believed that they had successfully managed to restrict Bracknor from diluting the share price I am quite sure that Bracknor would not have entered into an agreement if they believed that their hands were tied in any way, so they must have been confident that they could easily find a way round the short-selling restriction. This is how Bracknor operate; this is how they make their money. And this is how they destroy shareholder value for everyone else. | vatnabrekk |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions